Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

Understanding HCC: Perspectives on Diagnosis, Risk Factors, and Trea…

Yale Cancer Center

A. Jaffe

Combined Hepatocellular-Cholangiocarcinoma: Diagnosis and Management

Integrity CE

J. Birkness-Gartman

HCC Percutaneous Radio-Ablation Using BAT-90: Results of an Ongoing …

Malkhaz Mizandari

Advances in Hepatocellular Carcinoma Diagnosis and Treatment

Scripps Health

A. Singal

ASCO® GI 2024 Insights: "Evaluating Novel Therapies and ctDNA as a M…

Insights from 2024 ASCO® GI Annual Meeting

R. Mukherji

ASCO GI 2023 NRG/RTOG 1112 Randomized Phase 3 Study: Sorafenib vs. S…

ASCO GI 2023 Conference Coverage

L. Dawson

Approach to the Patient with a Liver Mass

Cedars Sinai

W. Ayoub

Advanced HCC: When to Switch to 2L Treatment - Case Presentation

COR2ED The Heart of Medical Education

T. Vandamme

Disparities Through GI Cancers: Panel Discussion

Total Health

R. Kim, J. Starr

Year in Review: GI Radiation Oncology

OncoAlert

E. Miller

Intermediate Stage HCC With No Hx of Cirrhosis: Case Presentation an…

Integrity CE

M. Baretti, D. Hsieh, K. Lafaro, F. Escorcia

New Guidelines in the Management of Liver Cancer

Yale Cancer Center

T. Taddei

The Global Landscape of Nonalcoholic Fatty Liver Disease: Results Fr…

Yichen Wang

Gallbladder and Bile Duct Cancer: Improving Screening & Treatment Op…

Oncology Data Advisor

M. Hadfield, W. Haque

Hepatocellular Carcinoma - From Screening to Treatment: Current Prac…

Yale Cancer Center

T. Taddei

Intermediate Stage HCC With a Hx of Cirrhosis: Case Presentation and…

Integrity CE

M. Baretti, D. Hsieh, K. Lafaro, F. Escorcia

ASCO® GI 2024 Insights: "Clinical Validation of Northstar Response, …

Insights from 2024 ASCO® GI Annual Meeting

I. Sahin

Local Ablative Treatment of Small Hepatocellular Carcinoma: What Are…

Houston Methodist

L. Kulik

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib i…

ASCO 2022 Conference Coverage

M. Rimini